Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats

AAPS PharmSci

Volumn 4, Issue 4, 2002, Pages

  Wang, Ellen Q ^a   Fung, Ho Leung ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Dependent diabetes; Mellitus; Nitrate tolerance; Nitric oxide; Noninsulin; Obesity; Zucker

Indexed keywords

DRUG VEHICLE; GLYCERYL TRINITRATE; ORGANIC NITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG SENSITIVITY; DRUG TOLERANCE; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OBESITY; PHARMACODYNAMICS; RAT; RAT STRAIN; REVIEW; STATISTICAL ANALYSIS; STEADY STATE; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; METABOLISM; SPRAGUE DAWLEY RAT; ZUCKER RAT;

ANALYSIS OF VARIANCE; ANIMALS; MALE; MODELS, ANIMAL; NITROGLYCERIN; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

EID: 85046916286     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps040428     Document Type: Review

References (41)

1. Rippe JM, Crossley S, Ringer R. Obesity as a chronic disease: modern medical and lifestyle management. J Am Diet Assoc. 1998;98:S9-15.
2. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898-904.
3. Garrison RJ, Higgins MW, Kannel WB. Obesity and coronary heart disease. Curr Opin Lipidol. 1996;7:199-202.
4. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635-643.
5. Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol. 1988;2:239-256.
6. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet. 2000;39:215-231.
7. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA. Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. J Pharmacol Exp Ther. 1984;231:649-653.
8. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA. Phenobarbital in the genetically obese Zucker rat. II. In vivo and in vitro assessments of microsomal enzyme induction. J Pharmacol Exp Ther. 1984;231:654-659.
9. Brunner LJ, Vadiei K, Luke DR. Cyclosporine disposition in the hyperlipidemic rat model. Res Commun Chem Pathol Pharmacol. 1988;59:339-348.
10. Chaudhary IP, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA. Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways. J Pharmacol Exp Ther. 1993;265:1333-1338.
11. Todd EL, Abernethy DR. Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. J Pharmacol Exp Ther. 1986;238:642-647.
12. Mathe D. Dyslipidemia and diabetes: animal models. Diabetes Metab. 1995;21:106-111.
13. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A. 1994;91:10878-10882.
14. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats: role of serine palmitoyltransferase overexpression. J Biol Chem. 1998;273:32487-32490.
15. Laight DW, Desai KM, Anggard EE, Carrier MJ. Endothelial dysfunction accompanies a pro-oxidant, pro-diabetic challenge in the insulin resistant, obese Zucker rat in vivo. Eur J Pharmacol. 2000;402:95-99.
16. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. Faseb J. 2001;15:312-321.
17. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:771-776.
18. McVeigh G, Brennan G, Hayes R, Johnston D. Primary nitrate tolerance in diabetes mellitus. Diabetologia. 1994;37:115-117.
19. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
20. Yap PS, Fung HL. Pharmacokinetics of nitroglycerin in rats. J Pharm Sci. 1978;67:584-586.
21. Bauer JA, Fung HL. Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure. J Pharmacol Exp Ther. 1991;256:249-254.
22. Booth BP, Jacob S, Bauer JA, Fung HL. Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol. 1996;28:432-438.
23. Wang EQ, Balthasar JP, Fung HL. Pharmacodynamic modeling of in vivo nitroglycerin (NTG) tolerance in conscious rats: effects of dose and dosage regimen [Abstract]. AAPSPharmSci. 2001;3:68.
24. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119:655-660.
25. Morley JE, Mattammal MB. Nitric oxide synthase levels in obese Zucker rats. Neurosci Lett. 1996;209:137-139.
26. Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord. 1999;23:936-942.
27. Hashimoto M, Akishita M, Eto M, et al. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord. 1998;22:477-484.
28. Ouchi Y, Han SZ, Kim S, et al. Augmented contractile function and abnormal Ca2+ handling in the aorta of Zucker obese rats with insulin resistance. Diabetes. 1996;45(suppl 3):S55-58.
29. Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev. 1998;14:241-249.
30. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84:3212-3216.
31. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28.
32. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
33. Laight DW, Kengatharan KM, Gopaul NK, Anggard EE, Carrier MJ. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol. 1998;125:895-901.
34. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 2001;50:159-165.
35. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-2610.
36. Bohlen HG, Lash JM. Endothelial-dependent vasodilation is preserved in non-insulin-dependent Zucker fatty diabetic rats. Am J Physiol. 1995;268:H2366-2374.
37. Avogaro A, Piarulli F, Valerio A, et al. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes. 1997;46:1040-1046.
38. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999;100:813-819.
39. Vincent HK, Powers SK, Stewart DJ, Shanely RA, Demirel H, Naito H. Obesity is associated with increased myocardial oxidative stress. Int J Obes Relat Metab Disord. 1999; 23:67-74.
40. Laight DW, Desai KM, Gopaul NK, Anggard EE, Carrier MJ. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. Eur J Pharmacol. 1999;377:89-92.
41. Giugliano D, Marfella R, Verrazzo G, et al. Abnormal rheologic effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and reversal by antioxidants. Ann Intern Med. 1995;123:338-343.